Patient V., 66 years old, has had diabetes mellitus since age 50. Previously took oral hypoglycemic agents, then was transferred to insulin therapy; administers fixed doses of short- and intermediate-acting insulin twice daily. Admitted with complaints of constant headache, palpitations, nausea, persistently high blood pressure (up to 200/130 mmHg) poorly controlled by antihypertensive therapy (receiving ACE inhibitors, thiazide diuretics, calcium channel blockers), fever up to 39.5°C, chills, and lumbar pain that started 4 days ago. Previously, leukocytes and bacteria were detected in urine; she was repeatedly treated with antibacterial agents and uroseptics. History includes multiple hospitalizations. Objective findings: ankle edema. Lungs: vesicular breath sounds, no wheezing. Heart sounds are muffled, rhythmic; accentuated second heart sound over the aorta. BP: 180/120 mmHg, heart rate: 75 bpm. Abdomen is soft, non-tender on palpation. Liver and spleen are not enlarged. Complete blood count: hemoglobin 92 g/L, erythrocytes 3.2×10¹²/L, leukocytes 15.0×10⁹/L, band neutrophils 6%, segmented neutrophils 76%, ESR 32 mm/h. Biochemical blood test: glucose 14 mmol/L, creatinine 152 µmol/L, total protein 82 g/L, albumin 50 g/L, potassium 5.6 mmol/L, sodium 129 mmol/L, chloride 96 mmol/L, bicarbonate 20 mmol/L, cholesterol 4.6 mmol/L, LDL 3.2 mmol/L, triglycerides 1.4 mmol/L, glycated hemoglobin 9.5%. Urinalysis: specific gravity 1015, proteinuria (1.5 g protein in 24-hour urine), urine glucose 10 mmol/L, no acetone in urine, bacteriuria, 150,000 leukocytes and 1,000 erythrocytes per 1 mL of urine. Renal ultrasound: right kidney 9.8×5.2 cm, left kidney 9.4×6.0 cm. Contours are smooth. Pyramids in both kidneys are prominent with halos of increased echogenicity. Questions: 1. Suggest the most probable preliminary diagnosis. 2. Justify the diagnosis you have made. 3. Develop and justify a plan for necessary additional examination of the patient before starting therapy and during treatment. 4. What would you recommend to the patient for treating this condition? Justify your choice. 5. What actions would you take in case of no response to the therapy you prescribed? Justify your choice.
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
I now have comprehensive information to provide a thorough clinical analysis. Let me synthesize the findings.
Clinical Case Analysis — Patient V., 66 years old
1. Most Probable Preliminary Diagnosis
Primary: Acute complicated pyelonephritis (bilateral), likely progressing toward urosepsis, against the background of:
- Type 2 Diabetes Mellitus (poorly controlled; HbA1c 9.5%), duration 16 years
- Diabetic nephropathy, stage of proteinuria (CKD stage G2–G3a, creatinine 152 µmol/L — eGFR ~35–38 mL/min)
- Diabetic nephropathy-associated renovascular hypertension (BP 200/130 mmHg, poorly controlled on triple therapy)
- Normochromic anemia (Hb 92 g/L) — likely anemia of CKD
Differential to exclude: Emphysematous pyelonephritis (given diabetes, gas-forming organisms, and recurrent/refractory course)
2. Justification of the Diagnosis
| Feature | Clinical Relevance |
|---|---|
| Fever 39.5°C, chills | Classic acute pyelonephritis presentation |
| Lumbar pain for 4 days | Renal capsular distension from bilateral inflammation |
| Leukocyturia (150,000/mL), bacteriuria, erythrocyturia (1,000/mL) | Active upper urinary tract infection |
| Leukocytosis 15.0×10⁹/L, band neutrophils 6%, ESR 32 mm/h | Bacterial infection with left shift — systemic inflammatory response |
| Proteinuria 1.5 g/24h | Combined diabetic nephropathy + inflammatory exudate |
| Glucose 14 mmol/L, HbA1c 9.5% | Poorly controlled DM — key predisposing factor |
| Creatinine 152 µmol/L | CKD, likely worsened acutely by sepsis/poor perfusion |
| Potassium 5.6 mmol/L, bicarbonate 20 mmol/L | Early metabolic acidosis + hyperkalemia from CKD |
| BP 200/130 mmHg, triple antihypertensive therapy | Renovascular hypertension + diabetic nephropathy |
| Ultrasound: bilateral enlarged pyramids with hyperechoic halos | Medullary edema characteristic of acute pyelonephritis — "halo sign" around pyramids |
| Previous repeated UTIs, antibacterial treatment | History of recurrent/complicated UTI, risk of resistant organisms |
| Sodium 129 mmol/L | Hyponatremia — sepsis-related or SIADH |
| Ankle edema | Hypoalbuminemia/nephropathy; also consider fluid retention from CKD |
The ultrasound finding of prominent pyramids with halos of increased echogenicity is the characteristic sonographic sign of acute pyelonephritis — representing focal interstitial edema and inflammatory infiltration of the renal medulla.
The combination of diabetes, bilateral involvement, failure of prior antibiotic courses, urosepsis criteria (fever >38.5°C, tachycardia, leukocytosis with shift), and renal impairment defines this as complicated pyelonephritis requiring hospitalization. The risk of emphysematous pyelonephritis must be excluded by CT.
3. Additional Examination Plan
Urgent / Pre-therapy Workup
| Investigation | Rationale |
|---|---|
| Blood cultures × 2 (aerobic + anaerobic) | Bacteremia present in 20–50% of complicated pyelonephritis; guides parenteral antibiotic choice; mandatory before starting antibiotics |
| Midstream urine culture + sensitivity | Identify causative organism (E. coli 45–54%, Klebsiella 26% in diabetics); sensitivity testing critical given prior antibiotic exposure |
| CT abdomen/pelvis with contrast (or non-contrast first) | Exclude emphysematous pyelonephritis, renal/perirenal abscess, xanthogranulomatous pyelonephritis, obstruction, or calculi — mandatory in diabetic patient not responding to antibiotics — CT is the most sensitive modality for these complications |
| Procalcitonin, CRP | Severity markers for sepsis; baseline for monitoring treatment response |
| Coagulation screen (PT, aPTT, fibrinogen, D-dimer) | Exclude DIC — high mortality in emphysematous/necrotizing pyelonephritis |
| Platelet count (part of CBC) | Poor prognostic factor if <60,000/µL in emphysematous pyelonephritis |
Metabolic/Renal Monitoring
| Investigation | Rationale |
|---|---|
| Repeat electrolytes q12–24h | Hyperkalemia (5.6) + bicarbonate 20 — monitor for worsening acidosis/K+ in CKD; ACE inhibitor may need to be temporarily held |
| 24-hour urine creatinine clearance or eGFR (CKD-EPI) | Baseline renal function for antibiotic dose adjustment |
| Serum glucose q4–6h; HbA1c already available | Tight glycemic control essential for infection resolution |
| Urinalysis repeat after 48–72h of treatment | Monitor sterilization of urine |
| Repeat urine culture 5–7 days into treatment | Confirm microbiological response |
Cardiovascular / Hypertension Workup
| Investigation | Rationale |
|---|---|
| ECG | Rule out LVH, ischemia; hyperkalemia-related changes |
| Echocardiography | Assess LV hypertrophy, diastolic dysfunction (muffled heart sounds, accentuated A2, severe hypertension) |
| Funduscopy | Assess hypertensive/diabetic retinopathy severity |
4. Treatment Plan
A. Hospitalization and Supportive Care
- Immediate hospitalization (severe sepsis criteria: fever >39°C, leukocytosis, hemodynamic instability risk, CKD)
- IV fluid resuscitation (NS or balanced crystalloids) guided by hemodynamic response and urine output — with caution given CKD and hypertension
- Strict monitoring: BP, temperature, HR, fluid balance, blood glucose, urine output
B. Antimicrobial Therapy (empirical, pre-culture)
Given complicated pyelonephritis with prior antibiotic exposure, DM, possible resistant organisms, and CKD:
First-line empirical IV antibiotics:
"If a patient has complicated pyelonephritis or requires hospitalization, parenteral antibiotics are recommended — fluoroquinolone, aminoglycoside ± ampicillin, extended-spectrum cephalosporin ± aminoglycoside, or a carbapenem." — Campbell-Walsh-Wein Urology
Recommended regimen:
- IV Ceftriaxone 1–2 g q24h (extended-spectrum cephalosporin; dose-adjust for eGFR ~37 mL/min — generally no adjustment needed for ceftriaxone)
- OR Piperacillin/tazobactam 4.5 g q8h IV if ESBL is suspected (prior repeated antibiotics = risk)
- OR Ertapenem 1 g q24h IV if prior fluoroquinolone/cephalosporin exposure raises resistance concern
- Avoid aminoglycosides as primary agent given CKD (nephrotoxic)
- Avoid fluoroquinolones if prior use documented (resistance likely)
- Adjust all doses to eGFR ~35–38 mL/min
Duration: Parenteral until clinically stable (afebrile ≥48h, leukocytosis resolving), then step down to oral agent guided by culture sensitivities for total 14 days (complicated pyelonephritis with DM).
C. Glycemic Control
- Transition from fixed-dose split insulin to a basal-bolus regimen with correction doses
- Target glucose 7.8–10 mmol/L during acute illness (per inpatient guidelines)
- Hyperglycemia (14 mmol/L) promotes bacterial growth and impairs neutrophil function — tight glycemic control is integral to infection resolution
- Ketonuria absent — no DKA
D. Antihypertensive Management
- Continue ACE inhibitor with caution — monitor potassium closely (currently 5.6 mmol/L; if rises above 6.0, hold ACEi)
- Calcium channel blocker (amlodipine): continue
- Consider replacing thiazide with loop diuretic (furosemide) — thiazides lose efficacy at eGFR <30–45; furosemide also addresses fluid retention
- Target BP <130/80 mmHg (diabetic nephropathy goal)
E. Anemia
- Hb 92 g/L with creatinine 152 — likely anemia of CKD + chronic inflammation
- Check iron stores, ferritin, transferrin saturation, reticulocyte count
- If iron-deficient: IV iron preferred over oral in CKD
- If erythropoietin deficiency: consider ESA once acute infection is controlled
5. If No Response to Therapy
No response is defined as: persistent fever and/or leukocytosis after 48–72 hours of adequate antibiotic therapy, clinical deterioration, or worsening renal function.
Step 1: Reassess the Diagnosis (Imaging)
- CT scan of abdomen/pelvis (contrast-enhanced) is mandatory — the most sensitive modality for:
- Emphysematous pyelonephritis — gas in renal parenchyma; management fundamentally changes
- Renal or perirenal abscess — requires drainage
- Obstruction / pyonephrosis — requires urgent decompression (ureteral stent or percutaneous nephrostomy)
- Xanthogranulomatous pyelonephritis — chronic destructive process mimicking carcinoma; managed surgically
Step 2: Microbiological Reassessment
- Review culture results; broaden empirical therapy if needed:
- If ESBL suspected or confirmed → Meropenem or Ertapenem
- If fungal UTI (candida) → consider Fluconazole (common in diabetics with prior antibiotic exposure)
- Repeat blood cultures if not already done
Step 3: Interventional Management
Per Brenner and Rector's The Kidney and Smith & Tanagho's General Urology:
- Emphysematous pyelonephritis: Percutaneous drainage is the recommended initial approach over emergency nephrectomy (mortality 13.5% with percutaneous drainage + antibiotics vs. 50% with antibiotics alone); requires 3–4 weeks of parenteral antibiotics
- Renal/perirenal abscess: Percutaneous catheter drainage (ultrasound or CT-guided); surgical drainage if inaccessible
- Obstruction: Emergency ureteral stenting or percutaneous nephrostomy
- Non-functioning kidney with severe emphysematous pyelonephritis + ≥2 poor prognostic factors (creatinine >1.4 [here 152 µmol/L = ~1.72 mg/dL], platelets <60,000, extensive gas pattern): Nephrectomy may be necessary
Step 4: Multidisciplinary Involvement
- Urology consultation (percutaneous drainage, possible nephrectomy)
- Nephrology consultation (renal replacement therapy readiness — acute-on-CKD)
- Endocrinology/diabetology (optimization of insulin regimen)
- Intensive care/HDU transfer if septic shock develops
Key References
- Brenner and Rector's The Kidney, 2-Volume Set — RENAL INFECTION; EMPHYSEMATOUS CYSTITIS AND PYELONEPHRITIS
- Campbell-Walsh-Wein Urology — Management of Pyelonephritis; Emphysematous Pyelonephritis
- Smith and Tanagho's General Urology, 19th Ed. — Emphysematous Pyelonephritis (p. 224)
This is a shared conversation. Sign in to Orris to start your own chat.